Since May 2023, it has been possible to submit applications for authorisation of veterinary medicinal products simultaneously to both Swissmedic and the UK Veterinary Medicines Directorate (VMD).
Applications will be reviewed independently (simultaneously) in close collaboration and according to the same time limit schedule. The new procedure means that expertise and resources can be pooled both by the authorities and by industry. While the two authorities take independent decisions on the authorisation, these are synchronised, enabling parallel market access in both countries. The aim of the collaboration is rapid access to safe veterinary medicinal products.
Interested companies can find further information in the joint Guidance Switzerland-United Kingdom Regulatory Cooperation: Guidance on Veterinary Drug Simultaneous Reviews.
This describes the collaboration process and supplements the legal and regulatory requirements for Switzerland and the UK.